LLY vs QDEL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
QuidelOrtho exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a technical trend score of 0/100. Despite appearing 'cheap' on a Price-to-Book (0.45) and Price-to-Sales (0.32) basis, the company suffers from negative profit margins (-41.45%) and a catastrophic 5-year price decline of 89.6%. The disconnect between the bullish analyst target ($30.83) and the deteriorating fundamental health suggests a classic value trap. The lack of revenue growth (2.2%) and negative ROE (-46.15%) further undermine any recovery thesis.
Compare Another Pair
Related Comparisons
LLY vs QDEL: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and QuidelOrtho Corporation (QDEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.